Competitor Analysis: Interferon

Publisher: La Merie Publishing
Pages: 89
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0047
Release Date: April of 2013

450.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Interferon

Product description

The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Interferon

Table of Contents

 1. Interferon alpha, beta and other sub-types

a)         INTERFERON alpha

  • Interferon alpha sales 2012 of branded products in regulated markets
  • 1st generation Interferon alpha-2a in regulated markets
  • 1st generation Interferon alpha-2a in non-regulated markets
  • Next generation Interferon alpha-2a in regulated markets
  • Next generation Interferon alpha-2a in non-regulated markets and biosimilars
  • 1st generation Interferon alpha-2b in regulated markets
  • 1st generation Interferon alpha-2b in non-regulated markets and biosimilars
  • Next generation Interferon alpha-2b in regulated markets
  • Next generation Interferon alpha-2b in non-regulated markets and biosimilars
  • Other Interferon alpha sub-types
  • Interferon alpha with not specified sub-type – 1/2
  • Purified natural human interferon alpha

b)         Consensus INTERFERONs

c)         INTERFERON beta

  • Interferon beta sales 2012 of branded products in regulated markets
  • 1st generation Interferon beta-1a in regulated markets
  • 1st generation Interferon beta-1a in non-regulated markets and biosimilars
  • 1st generation Interferon beta-1b in regulated markets
  • 1st generation Interferon beta-1b in non-regulated markets and biosimilars
  • 1st generation Interferon beta with not disclosed sub-type
  • Next generation Interferon beta in regulated markets
  • Purified natural human interferon beta

d)         INTERFERON gamma

e)         Other INTERFERONs

2.  Corporate Interferon Product Portfolios and R&D Pipelines

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top